CV Sciences Q1 revenue falls 11% on lower sales volume
CV SCIENCES INC CVSI | 0.00 |
Overview
US hemp wellness firm's Q1 revenue fell 11% yr/yr on lower sales volume due to restrictive regulations
Adjusted EBITDA loss narrowed, helped by lower operating expenses
Company completed debt restructuring to strengthen financial position
Outlook
Company expects gross margin improvement in the second half of 2026
Company remains focused on expense management and operational efficiency to achieve profitability
CV Sciences sees opportunities for growth through strategic acquisitions in current market environment
Result Drivers
REGULATORY IMPACT - Co said lower sales volume was driven by restrictive regulations at the federal level and in certain states
NEW PRODUCT CONTRIBUTION - 43% of net revenue in Q1 came from products launched since January 2023, per co
COST CONTROL - Reduced operating expenses by 13.3% yr/yr, which helped narrow adjusted EBITDA loss
Company press release: ID:nACSVGSmga
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Sales |
|
$3.20 mln |
|
Q1 Net Income |
|
-$643,000 |
|
Q1 Gross Profit |
|
$1.56 mln |
|
Q1 Operating Expenses |
|
$1.88 mln |
|
Q1 Operating Income |
|
-$318,000 |
|
Q1 Pretax Profit |
|
-$643,000 |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.